Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney Sells 55,615 Shares of Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney sold 55,615 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $3.36, for a total value of $186,866.40. Following the completion of the sale, the chief executive officer now directly owns 3,044,779 shares in the company, valued at $10,230,457.44. This trade represents a 1.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Organogenesis Price Performance

ORGO opened at $3.55 on Tuesday. The firm has a market cap of $470.66 million, a PE ratio of -59.17 and a beta of 1.73. The stock has a 50-day moving average price of $3.43 and a 200-day moving average price of $3.00. Organogenesis Holdings Inc. has a 1 year low of $2.16 and a 1 year high of $4.70. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.11. The business had revenue of $115.18 million during the quarter, compared to analysts’ expectations of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same period in the previous year, the company earned $0.02 earnings per share. Sell-side analysts predict that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Organogenesis

A number of hedge funds have recently added to or reduced their stakes in ORGO. Barclays PLC raised its stake in shares of Organogenesis by 251.7% in the third quarter. Barclays PLC now owns 94,809 shares of the company’s stock worth $271,000 after purchasing an additional 67,855 shares during the last quarter. Wellington Management Group LLP increased its holdings in Organogenesis by 8.0% in the 3rd quarter. Wellington Management Group LLP now owns 241,648 shares of the company’s stock worth $691,000 after buying an additional 17,842 shares in the last quarter. State Street Corp lifted its stake in Organogenesis by 0.6% during the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company’s stock valued at $4,175,000 after acquiring an additional 9,090 shares during the period. Verition Fund Management LLC boosted its holdings in shares of Organogenesis by 542.8% during the 3rd quarter. Verition Fund Management LLC now owns 78,690 shares of the company’s stock valued at $225,000 after acquiring an additional 66,448 shares during the last quarter. Finally, Captrust Financial Advisors purchased a new stake in shares of Organogenesis during the 3rd quarter valued at about $36,000. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.